Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Pushes For More EU Support For COVID-19 Vaccine Work

Agency Will Be Transparent On Assessment Process & Clinical Data

Executive Summary

Preparing for the assessment and post-approval monitoring of COVID-19 vaccines is taking up a lot of resources at the EMA, which has called on the European Commission to provide more support for such activities. The agency has also confirmed that no data have yet been submitted for its planned rolling reviews of potential vaccines.

You may also be interested in...



EU Politicians Squeeze Pharma Execs On Coronavirus Vaccine Contracts

With coronavirus cases again on the rise in many European countries, members of two EU parliamentary committees asked industry representatives to explain why details of COVID-19 vaccine supply agreements are being kept under wraps.

Coronavirus Notebook: EMA Expects First Vaccine Efficacy Data Soon, ACT-Accelerator Needs Urgent Funding

Talks are continuing on COVID-19 vaccine supply in the EU, with Pfizer/BioNTech’s BNT-162 the latest in the frame for the delivery of 200 million doses. The European Commission has also said that if the vaccines fail to perform, any money paid in advance purchase deals should go towards further research. 

MHRA Explains Entry Criteria for UK's New Innovative Medicines Pathway

A new licensing route is to be introduced by the UK MHRA next year for products that meet specific criteria, such as treating life threatening conditions or rare diseases and where there is a significant patient need. At a webinar this week, an MHRA medical assessor looked at the requirements that products will have to meet to enter the new pathway.

UsernamePublicRestriction

Register

MT142578

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel